Allergy and Immunology · Scottsdale, AZ
NPI
1396744249
Since 2005
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
7514 E Monterey Way, Suite 1
Scottsdale, AZ, 85251
Phone (480) 949-7377
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
88,342 services
Medicare patients, 2024
1,074
Average age 74
Drug cost, 2024
$9.5M
2,188 prescriptions
Company payments, 2025
$219K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael E Manning was code J2357 (injection, omalizumab, 5 mg), 30,375 times for 82 patients. In total Michael E Manning billed 88,342 services in 53 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2357 Injection, omalizumab, 5 mg | Office | 30,375 | 82 | $29.79 | $905K |
| J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 17,540 | 66 | $38.48 | $675K |
| J2356 Injection, tezepelumab-ekko, 1 mg | Office | 13,020 | 13 | $14.17 | $185K |
| J2182 Injection, mepolizumab, 1 mg | Office | 9,200 | 15 | $23.80 | $219K |
| 95165 Treatment - Miscellaneous | Office | 4,945 | 362 | $10.49 | $52K |
| 95117 Treatment - Miscellaneous | Office | 4,110 | 492 | $8.22 | $34K |
| 95004 Test - Miscellaneous | Office | 3,173 | 55 | $2.66 | $8,443 |
| J0517 Injection, benralizumab, 1 mg | Office | 1,410 | 13 | $131.12 | $185K |
| 96372 Injection Administration | Office | 863 | 119 | $9.94 | $8,574 |
| 95115 Treatment - Miscellaneous | Office | 639 | 83 | $6.99 | $4,464 |
| 99213 Office E&M - Established | Office | 577 | 416 | $64.89 | $37K |
| 96401 Chemotherapy Administration | Office | 453 | 107 | $53.77 | $24K |
| 96366 Intravenous Infusion, Hydration | Office | 345 | 64 | $15.56 | $5,367 |
| 96365 Intravenous Infusion, Hydration | Office | 250 | 67 | $47.68 | $12K |
| 95012 Pulmonary | Office | 102 | 88 | $13.99 | $1,427 |
By year: 2022 $3.9M for 116,961 services; 2023 $4.6M for 135,781 services; 2024 $2.4M for 88,342 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael E Manning prescribed most often to Medicare patients was Montelukast Sodium, with 221 prescriptions and refills. In total Michael E Manning wrote 2,188 Medicare prescriptions that cost $9.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 221 | 526 | 62 | $2,563 |
| Ipratropium Bromide Generic | 166 | 228 | 50 | $6,048 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 159 | 184 | 46 | $6,077 |
| Prednisone Generic | 111 | 125 | 59 | $403 |
| Azelastine Hcl Generic | 106 | 216 | 55 | $4,541 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 84 | 114 | 20 | $72K |
| Fluticasone Propionate Generic | 80 | 150 | 26 | $3,279 |
| Takhzyro Lanadelumab-Flyo | 71 | 71 | Under 11 | $3.7M |
| Azithromycin Generic | 66 | 71 | 31 | $328 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 55 | 90 | 15 | $12K |
| Breo Ellipta Fluticasone/Vilanterol | 48 | 68 | 12 | $26K |
| Spiriva Respimat Tiotropium Bromide | 48 | 92 | Under 11 | $47K |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 41 | 41 | 24 | $627 |
| Advair Hfa Fluticasone Propion/Salmeterol | 39 | 55 | Under 11 | $16K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 38 | 40 | Under 11 | $24K |
Brand drugs: - claims; generic drugs: 1,276 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael E Manning $219K ($184K in general payments such as food, travel and fees and $35K for research) from 25 companies. The largest payer was CSL Behring with $76K.
| Company | Payments | Amount |
|---|---|---|
| CSL Behring CSL.AX | 80 | $76K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 46 | $32K |
| Novartis Pharmaceuticals Corporation NVS | 35 | $25K |
| Pharming Healthcare, Inc. | 11 | $17K |
| Ionis Pharmaceuticals, Inc. IONS | 20 | $16K |
| BioCryst US Sales Co., LLC | 15 | $11K |
| Sanofi US Services Inc. SNY | 5 | $9,546 |
| AstraZeneca Pharmaceuticals LP AZN | 17 | $8,384 |
| GlaxoSmithKline, LLC. GSK | 29 | $5,536 |
| Regeneron Healthcare Solutions, Inc. REGN | 9 | $4,505 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.